Earlier quoted context omitted.
I think that depends on the theories that one has. Either choice would be based on missing or incomplete data. For example, one could question the potential for autoimmune conditions due to the way the mRNA vaccine works and how the immune system typically targets multiple proteins on the cell. There's no data or studies our there about this longterm possibility or even the incidence of autoimmune antibodies produced…
Could you explain what you mean by that? We already know Covid can cause autoimmune issues in some patients, so are you saying the effect you describe is just a subset of these, or different?
So all I'm saying is that the value proposition for an individual is based on the risks associated with vaccination or infection, and that the decision for people in age groups with the lowest known (short term) risks associated with infection have lower known benefits putting more emphasis on the unknown (longer term) risks or benefits. So for someone over 70 with about a 5% IFR, it's easy to say there is more benefit than risk because it's easy to see if a serious side effect is happening at a 5% rate or higher and the time horizon for longterm issues developing is limited by natural lifespan. With the quality of the VAERS data and the much longer time horizon, it's more difficult to discern a benefit for someone with an IFR of .002%. Of course we can't even look at the rates of many of the side effects to compare something other than IFR because the data data quality doesn't allow for that level of sensitivity.
Edit: why downvote?